World

Iceland resumes whaling amid growing opposition

Sep 02, 2023

Reykjavik [Iceland], September 2: Whaling ships in Iceland can resume the hunting of giant fin whales from September, following a two-month suspension by the government to assess whaling practices.
However, bad weather prevented the ships from leaving the port on Friday, according to the national broadcaster RUV.
The temporary suspension was prompted by a report in May highlighting the suffering of whales during capture. A working group established to investigate the issue later concluded that there is room for improvement in the hunting methods, therefore new regulations will be implemented with detailed and stricter requirements concerning equipment, hunting methods, and increased supervision, RUV reported.
According to a recent opinion poll, opposition to whaling has been growing in Iceland. In the survey conducted by the research company Maskina on behalf of the Iceland Nature Conservation Association in August, 42 percent of respondents expressed opposition to whaling and 29 percent were in favor. In May 2022, the ratio was 33 percent and 35 percent, respectively.
Prime Minister Katrin Jakobsdottir told RUV that a more comprehensive evaluation will be conducted at the end of the hunting season, particularly to ensure that the conditions set meet animal welfare standards.
The whaling season in Iceland usually lasts from June to late September. The current rules governing whaling licenses are set to expire at the end of the year.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025